The stock of Cognition Therapeutics Inc (CGTX) has gone down by -2.19% for the week, with a -19.69% drop in the past month and a 28.86% rise in the past quarter. The volatility ratio for the week is 7.10%, and the volatility levels for the past 30 days are 8.36% for CGTX. The simple moving average for the past 20 days is -10.55% for CGTX’s stock, with a -40.45% simple moving average for the past 200 days.
Is It Worth Investing in Cognition Therapeutics Inc (NASDAQ: CGTX) Right Now?
Company’s 36-month beta value is 0.94.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CGTX is 33.66M, and currently, short sellers hold a 1.56% ratio of that floaft. The average trading volume of CGTX on February 20, 2025 was 7.78M shares.
CGTX) stock’s latest price update
Cognition Therapeutics Inc (NASDAQ: CGTX) has experienced a decline in its stock price by -5.67 compared to its previous closing price of 0.63. However, the company has seen a fall of -2.19% in its stock price over the last five trading days. globenewswire.com reported 2025-01-30 that – Study demonstrated strong therapeutic responses across behavioral, functional, cognitive, and movement measures in patients with mild-to-moderate DLB –
Analysts’ Opinion of CGTX
Many brokerage firms have already submitted their reports for CGTX stocks, with B. Riley Securities repeating the rating for CGTX by listing it as a “Buy.” The predicted price for CGTX in the upcoming period, according to B. Riley Securities is $1.50 based on the research report published on December 19, 2024 of the previous year 2024.
Oppenheimer gave a rating of “Outperform” to CGTX, setting the target price at $22 in the report published on November 03rd of the previous year.
CGTX Trading at -9.66% from the 50-Day Moving Average
After a stumble in the market that brought CGTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.85% of loss for the given period.
Volatility was left at 8.36%, however, over the last 30 days, the volatility rate increased by 7.10%, as shares sank -22.12% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +58.45% upper at present.
During the last 5 trading sessions, CGTX fell by -1.40%, which changed the moving average for the period of 200-days by -69.74% in comparison to the 20-day moving average, which settled at $0.6647. In addition, Cognition Therapeutics Inc saw -15.26% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CGTX starting from Ricciardi Lisa, who purchase 38,851 shares at the price of $0.77 back on Jan 31 ’25. After this action, Ricciardi Lisa now owns 38,851 shares of Cognition Therapeutics Inc, valued at $30,001 using the latest closing price.
Ricciardi Lisa, the CEO & President of Cognition Therapeutics Inc, purchase 5,700 shares at $1.75 during a trade that took place back on Mar 14 ’24, which means that Ricciardi Lisa is holding 291,345 shares at $9,975 based on the most recent closing price.
Stock Fundamentals for CGTX
Current profitability levels for the company are sitting at:
- -157.08 for the present operating margin
- 0.49 for the gross margin
The net margin for Cognition Therapeutics Inc stands at -92.12. The total capital return value is set at -3.93. Equity return is now at value -157.90, with -103.30 for asset returns.
Based on Cognition Therapeutics Inc (CGTX), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -44.05. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -2014.9.
Currently, EBITDA for the company is -25.51 million with net debt to EBITDA at 0.63. When we switch over and look at the enterprise to sales, we see a ratio of 9.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.11.
Conclusion
In a nutshell, Cognition Therapeutics Inc (CGTX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
